Generic Name: Micardis
What is Micardis?
Renal impairment and kidney transplantationWhen Micardis is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Micardis in patients with recent kidney transplantation. Such conditions should be corrected before the administration of Micardis.
Dual blockade of the renin-angiotensin-aldosterone system RAAS There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function including acute renal failure.
Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended see sections 4. If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy. Other conditions with stimulation of the renin-angiotensin-aldosterone systemIn patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system e.
Otherwise, take the dose as soon as you remember, and then go back to taking it as you would normally. Do not take a double dose to make up for the dose that you missed. This may increase the chance of you getting unwanted side effects. If you have trouble remembering when to take your medicine, ask your pharmacist for some hints.
Immediately telephone your doctor or Poisons Information Centre telephone 13 11 26 for advice or go to Emergency at your nearest hospital, if you think that you or anyone else may have taken too much Micardis.
Do this even if there are no signs of discomfort or poisoning. You may experience rapid, shallow breathing or cold, clammy skin. This is because your blood pressure is too low. If you are about to be started on any new medicine, tell your doctor and pharmacist that you are taking Micardis. Tell any other doctors, dentists and pharmacists who treat you that you are taking Micardis. If you are going to have surgery, tell the surgeon or anaesthetist that you are taking Micardis.
How should I take Micardis?
Updated 6 days ago. I'm worried about what might happen. The NIH warns that you may experience more intense side effects than usual, which could include nausea, dizziness, headache, increased urination, and hypotension. How are you doing. It really depends on whether or not it is causing you any symptoms, according to the NIH, such as dizziness, headache, or fainting.
Are you experiencing any such symptoms.
What should I avoid while taking Micardis?
I ordered at that time and I am still receiving my medication from Universal Drugstore. I can't say enough about the extra fine service I have had with UDS. I have recommended UDS to several people. Even though only patients considered tolerant of both treatments were selected to enter ONTARGET R5. Commenting on the results, Professor Tony Dans, the ONTARGET R Trial coordinator for the Philippines, University of the Philippines College of Medicine said, "The new ONTARGET data are very important for treatment of Asian patients at risk of cardiovascular disease.
Long-term efficacy and tolerability of treatment in these patients is of prime importance to ensure that they remain on their medication and are well protected.
Micardis side effects
Initial dose: 40 mg orally once a day with or without food, assuming adequate intravascular volume Maintenance dose: 20 mg to 80 mg orally once a dayCardiovascular risk reduction in patients unable to take ACE inhibitors: 80 mg orally once a day with or without food It is unknown whether doses lower than 80 mg are effective in reducing the risk of cardiovascular morbidity or mortality.
When initiating Micardis for cardiovascular risk reduction, monitoring of blood pressure is recommended, and appropriate adjustment of medications that lower blood pressure may be necessary. See also: Dosage Information in more detail Take the missed dose as soon as you remember.
Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose. It can lower your blood pressure and may increase some of the side effects of Micardis.
Common Micardis ide effects may include:
If you forget to take it If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.
If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
Telmisartan should be kept in the sealed blister due to the hygroscopic property of the tablets.
You may feel dizzy or lightheaded when you begin to take Micardis, especially if you are also taking a diuretic or fluid tablet.
Telmisartan determina una diminuzione nei livelli plasmatici di aldosterone. Telmisartan non inibisce l'enzima di conversione dell'angiotensina chininasi IIenzima che degrada anche la bradichinina. ONTARGET ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial ha confrontato gli effetti di telmisartan, ramipril e della combinazione di telmisartan e ramipril sugli esiti cardiovascolari in 25.
Telmisartan ha mostrato un'efficacia simile a ramipril nel ridurre l'endpoint primario composito di morte cardiovascolare, infarto miocardico non-fatale, ictus non-fatale o ospedalizzazione per insufficienza cardiaca congestizia. L'associazione di telmisartan e ramipril non ha aggiunto alcun beneficio rispetto a ramipril o telmisartan in monoterapia.
Where can I get more information?
Do not take Micardisif you are allergic hypersensitive to telmisartan or any other ingredients included in Micardis tablets see section Further information for a list of other ingredients.
Currently available data are described in section 5.